KCNH2 and breast cancer: However,since CGRP receptors mediate pain, particularly bone pain in metastaticcancers, this may be an additional benefit for therapy in oncology.Finally, although we have previously shown the full drug-like properties(ADME, hERG, and PK) and selectivity profile of compound 25 and the effects of this compound class in pancreatic cancer cellviability and apoptosis in both in vitro and in vivo tumor growth models,34 we demonstrate here that similar potent antitumor effects are alsoobserved in breast cancer models using the highly aggressive triple-negativebreast cancer cell line MDA-MB-231.